Casdin Capital, LLC Alnylam Pharmaceuticals, Inc. Transaction History

Casdin Capital, LLC

$1.16 Billion
Q4 2024

A detailed history of Casdin Capital, LLC transactions in Alnylam Pharmaceuticals, Inc. stock. As of the latest transaction made, Casdin Capital, LLC holds 140,000 shares of ALNY stock, worth $34.9 Million. This represents 2.83% of its overall portfolio holdings.

Number of Shares

140,000

Previous 170,000 17.65%

Holding current value

$34.9 Million

Previous $46.8 Million 29.55%

% of portfolio

2.83%

Previous 3.63%

24 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2024 Feb 14, 2025	SELL	$232.27 - $300.43 $6.97 Million - $9.01 Million	-30,000 Reduced 17.65%	140,000 $32.9 Million
Q2 2024 Aug 14, 2024	SELL	$143.31 - $247.0 $26.9 Million - $46.4 Million	-188,000 Reduced 52.51%	170,000 $41.3 Million
Q1 2024 May 15, 2024	BUY	$146.51 - $198.2 $23.9 Million - $32.3 Million	163,000 Added 83.59%	358,000 $53.5 Million
Q4 2023 Feb 14, 2024	SELL	$151.41 - $196.57 $757,050 - $982,850	-5,000 Reduced 2.5%	195,000 $37.3 Million
Q3 2023 Nov 14, 2023	SELL	$170.77 - $211.65 $13.7 Million - $16.9 Million	-80,000 Reduced 28.57%	200,000 $35.4 Million
Q2 2023 Aug 14, 2023	BUY	$185.01 - $212.05 $1.85 Million - $2.12 Million	10,000 Added 3.7%	280,000 $53.2 Million
Q1 2023 May 15, 2023	SELL	$182.66 - $235.53 $17.4 Million - $22.4 Million	-95,000 Reduced 26.03%	270,000 $54.1 Million
Q4 2022 Feb 14, 2023	SELL	$185.53 - $241.31 $52.5 Million - $68.3 Million	-283,000 Reduced 43.67%	365,000 $86.7 Million
Q3 2022 Nov 14, 2022	SELL	$138.54 - $232.0 $21.8 Million - $36.4 Million	-157,000 Reduced 19.5%	648,000 $130 Million
Q2 2022 Aug 15, 2022	SELL	$120.42 - $169.29 $23.5 Million - $33 Million	-195,000 Reduced 19.5%	805,000 $117 Million
Q2 2021 Aug 16, 2021	BUY	$128.63 - $176.89 $15.4 Million - $21.2 Million	120,000 Added 13.64%	1,000,000 $170 Million
Q1 2021 May 17, 2021	BUY	$126.83 - $175.69 $12.7 Million - $17.6 Million	100,000 Added 12.82%	880,000 $124 Million
Q4 2020 Feb 16, 2021	BUY	$122.97 - $147.0 $19.7 Million - $23.5 Million	160,000 Added 25.81%	780,000 $101 Million
Q3 2020 Nov 16, 2020	BUY	$121.19 - $165.49 $8.48 Million - $11.6 Million	70,000 Added 12.73%	620,000 $90.3 Million
Q2 2020 Aug 14, 2020	SELL	$104.21 - $156.44 $3.65 Million - $5.48 Million	-35,000 Reduced 5.98%	550,000 $81.5 Million
Q1 2020 May 15, 2020	BUY	$93.12 - $133.99 $6.52 Million - $9.38 Million	70,000 Added 13.59%	585,000 $63.7 Million
Q4 2019 Feb 14, 2020	SELL	$74.51 - $124.23 $6.33 Million - $10.6 Million	-85,000 Reduced 14.17%	515,000 $59.3 Million
Q3 2019 Nov 12, 2019	SELL	$70.9 - $87.82 $3.55 Million - $4.39 Million	-50,000 Reduced 7.69%	600,000 $48.3 Billion
Q2 2019 Aug 13, 2019	BUY	$65.86 - $92.79 $13.5 Million - $19 Million	205,000 Added 46.07%	650,000 $0
Q1 2019 May 15, 2019	BUY	$72.76 - $93.45 $6.55 Million - $8.41 Million	90,000 Added 25.35%	445,000 $41.6 Million
Q4 2018 Feb 13, 2019	BUY	$62.67 - $88.33 $5.33 Million - $7.51 Million	85,000 Added 31.48%	355,000 $25.9 Million
Q2 2018 Aug 14, 2018	BUY	$88.31 - $107.8 $1.77 Million - $2.16 Million	20,000 Added 8.0%	270,000 $26.6 Million
Q1 2018 May 15, 2018	BUY	$115.92 - $148.54 $5.8 Million - $7.43 Million	50,000 Added 25.0%	250,000 $29.8 Million
Q3 2017 Nov 14, 2017	BUY	$72.53 - $118.27 $14.5 Million - $23.7 Million	200,000	200,000 $23.5 Million

Others Institutions Holding ALNY

# of Institutions

669

Shares Held

112M

Call Options Held

839K

Put Options Held

771K

View Full List

About ALNYLAM PHARMACEUTICALS, INC.

Ticker ALNY
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 123,028,000
Market Cap $30.7B
Description
Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. The company's pipeline of investigational RNAi therapeutics focuses on genetic medicines, cardio-metabolic diseases, hepatic infectious diseases, and central nervous system...

More about ALNY

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Casdin Capital, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Casdin Capital, LLC with notifications on news.

Account

Casdin Capital, LLC Alnylam Pharmaceuticals, Inc. Transaction History